Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease

Journal of Neural Transmission

Volumn 113, Issue 2, 2006, Pages 231-238

  Kolsch H ^a   Lutjohann D ^a   Jessen, F ^a   Urbach, H ^a   Von Bergmann, K ^a   Maier, W ^a   Heun, R ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer's disease; Cholesterol; Neuropeptide Y; Polymorphism

Indexed keywords

CHOLESTEROL; CHOLESTEROL DERIVATIVE; NEUROPEPTIDE Y;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ALZHEIMER DISEASE; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYCHOLESTEROLS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 31044446701     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-005-0319-z     Document Type: Article

References (28)

1. M Citron D Westway X Weiming G Carlson T Diehl G Levesque K Johnson-Wood M Lee P Seubert A Davis D Kholodenko R Motier R Sherrington B Perry H Yao R Strome I Lieberburg J Rommens S Kim D Schenk P Fraser PG Hyslop DJ Selkoe 1997 Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Med 3 67 72
2. M Diez S Danner P Frey B Sommer M Staufenbiel KH Wiederhold T Hokfelt 2003 Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol Dis 14 579 594
3. B Ding 2003 Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm 110 1199 1204
4. S Dzeletovic O Breuer E Lund U Diczfalusy 1995 Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem 225 73 80
5. AT Erkkila V Lindi S Lehto M Laakso MI Uusitupa 2002 Association of leucine 7 to proline 7 polymorphism in the preproneuropeptide Y with serum lipids in patients with coronary heart disease. Mol Genet Metab 75 260 264
6. K Fassbender M Simons C Bergmann M Stroick D Lütjohann P Keller H Runz S Kuhl T Bertsch K Von Bergmann M Hennerici K Beyreuther T Hartmann 2001 Simvastatin strongly reduces levels of Alzheimer's disease beta - amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98 5856 5861
7. MF Folstein SE Folstein PR McHugh 1975 "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 189 198
8. AM Goate 1998 Monogenetic determinants of Alzheimer's disease: APP mutations. Cell Mol Life Sci 54 897 901
9. N Hamajima T Saito K Matsuo K Kozaki T Takahashi K Tajima 2000 Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Res 91 865 868
10. S Helisalmi R Valve MK Karvonen M Hiltunen M Pirskanen A Mannermaa M Koulu U Pesonen M Uusitupa H Soininen 2000 The leucine (7)-to-proline (7) polymorphism in the signal peptide of neuropeptide Y is not associated with Alzheimer's disease or the link apolipoprotein E. Neurosci Lett 287 25 28
11. JE Hixson DT Vernier 1990 Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31 545 548
12. H Jick GL Zornberg SS Jick S Seshadri DA Drachman 2000 Statins and the risk of dementia. Lancet 356 1627 1631
13. MK Karvonen U Pesonen M Koulu L Niskanen M Laakso A Rissanen JM Dekker LM Hart R Valve MI Uusitupa 1998 Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 4 1434 1437
14. M Kivipelto EL Helkala MP Laakso T Hanninen M Hallikainen K Alhainen H Soininen J Tuomilehto A Nissinen 2001 Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322 1447 1451
15. V Leoni T Masterman FS Mousavi B Wretlind LO Wahlund U Diczfalusy J Hillert I Björkhem 2004 Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 42 186 191
16. G Li R Higdon WA Kukull E Peskind MK Van Valen D Tsuang G Van Belle W McCormick JD Bowen L Teri GD Schellenberg EB Larson 2004 Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 1624 1628
17. D Lütjohann O Breuer G Ahlborg I Nennesmo A Sidén U Diczfalusy I Björkhem 1996 Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 93 9799 9804
18. G McKhann D Drachman M Folstein R Katzman D Price EM Stadlan 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 939 944
19. L Minthon L Edvinsson L Gustafson 1997 Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord 8 232 239
20. CL Nilsson A Brinkmalm L Minthon K Blennow R Ekman 2001 Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Peptides 22 2105 2112
21. IL Notkola R Sulkava J Pekkanen T Erkinjuntti C Ehnholm P Kivinen A Tuomilehto A Nissinen 1998 Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease. Neuroepidemiology 17 14 20
22. M Simons P Keller B De Strooper K Beyreuther CG Dotti K Simons 1998 Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95 6460 6464
23. WJ Strittmatter KH Weisgraber DY Huang L-M Dong GS Salvesen M Pericak-Vance D Schmechel AM Saunders D Goldgraber AD Roses 1993a Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90 8098 8102
24. WJ Strittmatter AM Saunders D Schmechel M Pericak-Vance J Enghild GS Salvesen AD Roses 1993b Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90 1977 1981
25. RE Tanzi L Bertram 2001 New frontiers in Alzheimer's disease genetics. Neuron 32 181 184
26. SM Wallerstedt S Skrtic AL Eriksson C Ohlsson T Hedner 2004 Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 22 1277 1281
27. B Wolozin W Kellman P Ruosseau GG Celesia G Siegel 2000 Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57 1439 1443
28. JL Zhuo 2004 Neuropeptide Y T1128C polymorphism: an independent predictor of hypertensive and cardiovascular diseases? J Hypertens 22 1251 1253